Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 1/20 | 0.51 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.51 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | MGLL | Q99685 | 9/20 | 0.44 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30857635 | 0.85 | CHRM1 (0.49) | SLC6A4SLC6A3KDM2BMGLL | |
| SCHEMBL16300046 | 0.85 | CHRM1 (0.49) | SLC6A4SLC6A3KDM2BMGLL | |
| SCHEMBL11679259 | 0.79 | HPGD (0.57) | KDM2BALDH1A1RAB9AMGLLHPGD | |
| SCHEMBL3389632 | 0.77 | KDM2B (0.57) | KDM2BALDH1A1RAB9AGAAMGLL | |
| SCHEMBL30857609 | 0.76 | MGLL (0.50) | KDM2BALDH1A1MEN1KMT2ALMNA | |
| SCHEMBL16422900 | 0.76 | MGLL (0.58) | KDM2BALDH1A1SMN1; SMN2RAB9AMEN1 | |
| SCHEMBL30857687 | 0.75 | STS (0.57) | MEN1KMT2ANPSR1MGLLHPGD | |
| SCHEMBL17763543 | 0.75 | KDM2B (0.46) | KDM2BALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL10631889 | 0.75 | SLC6A4 (0.66) | SLC6A4SLC6A3SMN1; SMN2MEN1KMT2A | |
| SCHEMBL14141253 | 0.74 | ALDH1A1 (0.52) | ALDH1A1SMN1; SMN2RAB9ALMNATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160176906-A1 | Chemical Compounds | ASTRAZENECA AB (SE) | 2016-06-23 | — | — | US | disclosed |
| US-9248140-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2016-02-02 | — | — | US | disclosed |
| US-20150328239-A1 | Chemical Compounds | ASTRAZENECA AB (SE) | 2015-11-19 | — | — | US | disclosed |
| US-9018381-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2015-04-28 | — | — | US | disclosed |
| US-20130310344-A1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | ASTRAZENECA AB (UK) | 2013-11-21 | — | — | US | disclosed |
| US-20120035134-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2012-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035134-A1 | CHEMICAL COMPOUNDS | BCL2, BCL2L1, BAX | SLC6A4 4260/4885SLC6A3 3880/4885KDM2B 1415/4885 |
| US-20150328239-A1 | Chemical Compounds | BCL2, BCL2L1, BAX | SLC6A4 4260/4885SLC6A3 3880/4885KDM2B 1415/4885 |
| US-20160176906-A1 | Chemical Compounds | BCL2, BCL2L1, BAX | SLC6A4 4260/4885SLC6A3 3880/4885KDM2B 1415/4885 |
| US-20130310344-A1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | BCL2, BAX, BCLAF1 | SLC6A4 3815/4885SLC6A3 4230/4885KDM2B 763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.